James Hardie Industries plc. Ordinary Shares vs Twist Bioscience Corp — how do they compare? James Hardie Industries plc. Ordinary Shares trades at $24.75 (market cap $14.60B), while Twist Bioscience Corp trades at $166.14 (market cap $10.08B). The key difference: James Hardie Industries plc. Ordinary Shares is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, James Hardie Industries plc. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold James Hardie Industries plc. Ordinary Shares for 0 Days and Twist Bioscience Corp for 27 Days on average.
| JHX | TWST | |
|---|---|---|
Market Cap | $14.60B | $10.08B |
Volume | 7,262,924 | 4,229,037 |
Sector | Basic Materials | Health |
52-Week High | $31.08 | $205.00 |
52-Week Low | $16.69 | $25.45 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $18.83B | $10.01B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
James Hardie manufactures fiber cement products for residential and commercial construction. Its portfolio includes exterior siding, interior boards, and other building materials.
Read more on JHX →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →